Olaparib maintenance therapy for platinum-sensitive relapsed ovarian cancer at a single institution: A retrospective study.
Takahiro KatsudaShin NishioShingo TasakiJongmyung ParkKazuto TasakiNaotake TsudaKimio UshijimaPublished in: The journal of obstetrics and gynaecology research (2024)
Olaparib maintenance therapy for recurrent platinum-sensitive ovarian cancer at our institution was effective, with acceptable adverse events. HRD was the most significant prognostic factor for patients with recurrent platinum-sensitive ovarian cancer.